

Supplementary Table 1. All events during or after treatment of both treatment group

	PHY (33)	UNI (82)
Disease progression during treatment	5 (15.2%)	8 (9.8%)
Progression from PR/SD	7 (21.2%)	7 (8.5%)
Relapse from CR	4 (12.1%)	17 (20.7%)
Discontinuation of therapy	8 (24.2%)	4 (4.9%)
Death during treatment	1 (3.0%)	4 (4.9%)
Death during CR	0 (0%)	2 (2.4%)
No event	8 (24.2%)	40 (48.8%)
Total	33 (100%)	82 (100%)

CR: complete remission, PHY: physicians' decision group, RP: partial remission, SD: stable disease, UNI: unified dose attenuation group